PRINSTON PHARMACEUTICAL ANNOUNCES THE APPROVAL OF GENERIC KEPPRA XR® EXTENDED-RELEASE TABLETS IN THE UNITED STATES
CRANBURY, NJ – May 21, 2015 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) have approved its generic equivalent of Keppra XR® (Levetiracetam Extended-Release Tablets USP), 500 mg and 750 mg. The Company is preparing for commercialization of this product through Prinston's generic division, Solco Healthcare, LLC.
"The approval of Levetiracetam Extended-release tablets continues to support our strategy of developing technology distinguished generics. We look forward to launching this important product with plans to begin shipping in early third quarter of 2015", said Jun Du, President and Chief Executive Officer of Prinston.
According to IMS Health (NSP), U.S. brand and generic sales of levetiracetam extended-release tablets products were approximately $118.2 million for the 12 months ending in April 2015.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet